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COMMENTARYCommentaryCameron D. Wright, MDMineo and Ambrogi1 report an unusual series—that of
class I patients with myasthenia gravis (ocular symptoms
only) treated with a transsternal extended thymectomy
(T-3b thymectomy) compared with patients with similar
clinical characteristics who refused operation. This is a rel-
atively large series of patients with class I myasthenia
treated by an aggressive T-3b thymectomy in a center of ex-
cellence for thymic disorders. There was minimal major
morbidity (4%), no deaths, and the mean length of stay
was 6.1 days (4.1 days). Their definition of a stable remis-
sion (their surrogate for a complete remission) was no
symptoms for at least 12 months without therapy except
for an allowance for low-dose steroids. As such, their series
will not be strictly comparable with other modern series be-
cause this is not the strict Myasthenia Gravis Foundation of
America (MGFA) definition of a complete remission. There
was no difference in total remission rates between the 2
groups; 64% of operated versus 55% of nonoperated pa-
tients achieved a stable remission (P ¼ .35). There was no
difference in 5-year MGFA class progression—19% in
operated and 26% in nonoperated patients (P ¼ .41). Al-
though there was no difference in stable remission rates in
the Cox analysis with unlimited follow-up, there was a dif-
ference if the follow-up was limited to 5 years (P¼ .41). Pa-
tients who were diagnosed and treated early (<6 months)
did better than those treated later. My own analysis of these
somewhat disappointing results is that many patients with
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The Journal of Thoracic and Carand aggressive thymectomy does not improve the complete
remission rate markedly. As such, I believe the patients who
opted for nonoperative treatment made a wise choice.
The most interesting aspect of this article is the poor re-
sults in patients who had ectopic thymus despite a very ag-
gressive thymectomy. Of the 22 patients with ectopic
thymus (47% of all patients), only 13 improved after thy-
mectomy whereas all 25 improved in those without ectopic
thymus. These sobering results cast doubt on the hypothesis
that a radical thymectomy improves outcomes by removing
more thymic tissue than standard thymectomies. Thought-
ful surgeons realize that it is impossible to remove all ec-
topic thymic tissue from the mediastinum and, in the end,
it is a matter of degree of how much fatty tissue can be re-
moved safely. However, the more radical removal comes at
the cost of a larger operation that cannot be accomplished
byminimally invasivemeans (either transcervical or by uni-
lateral video-assisted thoracoscopic surgery) with a longer
length of stay and recovery time. Unfortunately, it is cur-
rently not possible to predict preoperatively who has ectopic
thymic tissue. My judgment, given these results, leads me to
lend more weight to the argument favoring minimally inva-
sive approaches to removing the thymus for myasthenia
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